Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial Commentaries

“The Lower the BP the Better” Paradigm in the Elderly

Vanished by VALISH?

Fabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.110.150763
Hypertension. 2010;56:182-184
Originally published June 7, 2010
Fabio Angeli
From the Department of Cardiology and Clinical Research Unit-Preventive Cardiology (F.A.), Hospital “S Maria della Misericordia,” Perugia, Italy; Department of Medicine (P.V.), Hospital of Assisi, Assisi, Italy; Department of Internal Medicine (G.R.), University of Perugia, Perugia, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gianpaolo Reboldi
From the Department of Cardiology and Clinical Research Unit-Preventive Cardiology (F.A.), Hospital “S Maria della Misericordia,” Perugia, Italy; Department of Medicine (P.V.), Hospital of Assisi, Assisi, Italy; Department of Internal Medicine (G.R.), University of Perugia, Perugia, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Verdecchia
From the Department of Cardiology and Clinical Research Unit-Preventive Cardiology (F.A.), Hospital “S Maria della Misericordia,” Perugia, Italy; Department of Medicine (P.V.), Hospital of Assisi, Assisi, Italy; Department of Internal Medicine (G.R.), University of Perugia, Perugia, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Treating Hypertension in Elderly
    • Does Evidence Support an Aggressive Systolic BP Target in the Elderly?
    • What to Conclude, Then?
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

If a man will begin with certainties, he shall end in doubts; but if he will be content to begin with doubts, he shall end in certainties.— —Francis Bacon, The Advancement of Learning, year 1605

Hypertension is a growing public health problem in elderly people, with a prevalence up to 80% in individuals aged ≥70 years. Isolated systolic hypertension accounts for 60% to 75% of cases, systolic blood pressure (BP) being the dominant prognostic marker.1 Unfortunately, the rate of hypertension control only minimally improved over last year’s in elderly subjects when compared with the younger people.2

Treating Hypertension in Elderly

Several randomized clinical trials tested the benefit of treatment in elderly patients with isolated systolic hypertension or systolic-diastolic hypertension. Staessen et al3 reviewed 8 randomized clinical trials carried out in patients with isolated systolic hypertension and aged ≥60 years. Active treatment reduced total mortality by 13%, cardiovascular (CV) mortality by 18%, all CV complications by 26%, stroke by 30%, and coronary events by 23%. The benefits of treatment in octogenarians remained unproved for years up to the results of the Hypertension in the Very Elderly Trial, in which 3845 patients aged ≥80 years with systolic BP ≥160 mm Hg were randomized to indapamide or placebo. Perindopril or matching placebo was added if necessary to achieve the target BP of 150/80 mm Hg. The trial was stopped after less than 2 years of follow-up because of a beneficial effect of treatment on several outcomes including all-cause mortality, although the primary study outcome, fatal or nonfatal stroke, was only marginally reduced (by 30%; P=0.06). At study end, BP was lower by 15.0/6.1 mm Hg in the treatment group than in the placebo group.4 The results of Hypertension in the Very Elderly Trial extend the benefits of treatment to octogenarians with systolic BP ≥160 mm Hg. More recently, the Blood Pressure Lowering Treatment Trialists’ Collaboration reviewed 31 trials, for a total of 190 606 participants, and concluded that, for any given reduction in systolic BP, the protection afforded by antihypertensive treatment is comparable in younger (<65 years) and older (≥65 years) adults.5

It is now generally accepted that, despite some minor differences between different classes of antihypertensive drugs in the risk of stroke and coronary artery disease,6 most of the outcome benefit of antihypertensive treatment is explained by the degree of systolic BP reduction.1 A recent meta-analysis of 147 randomized trials showed that a reduction in systolic BP by 10 mm Hg leads to a 25% relative risk reduction in coronary heart disease and a 35% to 40% relative risk reduction in stroke.7

Does Evidence Support an Aggressive Systolic BP Target in the Elderly?

Although the current guidelines suggest that systolic BP should be lowered below 140 mm Hg in the elderly,1 supporting evidence is scanty. As suggested by Zanchetti et al,8 3 points should be considered: (1) not a single trial was specifically conducted in elderly hypertensive patients with systolic BP <160 mm Hg; (2) in none of the available placebo-controlled trials did systolic BP fall below 140 mm Hg in the control group; and (3) in none of the available placebo-controlled trials was 140 mm Hg the prespecified BP target of treatment.

The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients9 was conducted in hypertensive patients aged 60 to 85 years with systolic BP ≥160 mm Hg. Patients were randomized to a more tight (<140 mm Hg) or less tight (140 to 160 mm Hg) systolic BP target and followed for 2 years. The primary end point, a composite of CV disease and renal failure, did not differ between the 2 groups. This study cannot be considered as definitive because of the relatively short duration of follow-up, the inclusion of patients with complicated hypertension, and the underuse of diuretics (12.1%). In the Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control, a more aggressive systolic BP target (<130 mm Hg) was superior to a less aggressive target (<140 mm Hg) in reducing left ventricular hypertrophy, the primary outcome of the study, in a relatively younger population (≥55 years of age; mean age: 67 years) of patients with systolic BP >150 mm Hg.10 In this study, coronary revascularization (P=0.032) and new-onset atrial fibrillation (P=0.044), 2 secondary outcomes, were less common in patients randomized to the more aggressive target.10

The picture is complicated by the results of the Valsartan in Elderly Isolated Systolic Hypertension (VALISH) Study,11 published in the present issue of Hypertension. Overall, 3260 patients aged 70 to 84 years were randomized to a more tight (<140 mm Hg) or less tight (140 to 150 mm Hg) systolic BP control. Valsartan was the first-line drug in all of the patients, with possible combination with other drugs, except other angiotensin receptor blockers, to achieve the assigned BP target (Figure). At the end of the study (median follow-up: 3 years), systolic BP decreased by 5.4 mm Hg more in the tight BP control group, but the primary outcome, a composite of fatal and nonfatal CV disease and renal failure, was only modestly reduced in the more tight control group (10.6 versus 12.0 per 1000 patient-years; P=0.38). One potential limitation of the VALISH Study11 was the observed rate of primary outcome, which was half of that expected (10.6 versus 21.4 per 1000 patient-years in the more tight and 12.0 versus 29.1 per 1000 patient-years in the less tight BP control group). This could have reduced the power of the study to detect significant outcome differences between the groups, if truly present. The relatively low event rate might be explained by a low prevalence of patients with established CV disease at entry (Figure).

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure. Main features and limitations of the VALISH Trial.

Another point that deserves mention is the use of an angiotensin receptor blocker (valsartan) at relatively low daily doses as initial therapy for all of the patients (40 to 80 mg once daily). Calcium-channel blockers and diuretics may be preferential drugs for older hypertensive patients when compared with drugs that inhibit the renin-angiotensin system.12 Furthermore, low daily doses of angiotensin receptor blockers, as those used in the VALISH Study,11 are generally considered scarcely effective in US and European patients,13 and, hence, the extrapolation of these data to non-Asian populations may not be automatic.

What to Conclude, Then?

On balance, none of the available intervention trials provided strong support for ambitious BP targets in elderly patients with systolic hypertension. It is clear that the absolute CV risk is higher in elderly patients than in the younger ones, particularly in the presence of comorbidities or other risk factors. Consequently, if we assume that the relative benefit of treatment does not change with age,5 then the absolute benefit of treatment in the elderly for any given reduction of BP would be greater, and the number of patients to treat to prevent one event would be lower. The outcome benefits of systolic BP reduction in the elderly are well established.3 The current uncertainty surrounding the definition of the most appropriate systolic BP target, highlighted by the few available trials9,10⇓ including VALISH,11 should be perceived as a stimulus for future research, not as an argument vanishing or questioning the benefit of treatment. Paraphrasing Sir Francis Bacon, we should be content to enter this arena with doubts, not with certainties. The systolic BP target of 140 mm Hg in the elderly, although recommended by guidelines, remains largely unsupported.8 More stringent targets, although reasonable and potentially affordable, require evidence from clinical trials.

Acknowledgments

Sources of Funding

This article was supported in part by the no-profit foundation “Fondazione Umbra Cuore e Ipertensione-ONLUS,” Perugia, Italy.

Disclosures

None.

Footnotes

  • The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

References

  1. ↵
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206–1252.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Campbell NR, Khan NA, Hill MD, Tremblay G, Lebel M, Kaczorowski J, McAlister FA, Lewanczuk RZ, Tobe S. 2009 Canadian Hypertension Education Program recommendations: the scientific summary–an annual update. Can J Cardiol. 2009; 25: 271–277.
    OpenUrlCrossRefPubMed
  3. ↵
    Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000; 355: 865–872.
    OpenUrlCrossRefPubMed
  4. ↵
    Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358: 1887–1898.
    OpenUrlCrossRefPubMed
  5. ↵
    Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008; 336: 1121–1123.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, Staessen JA, Porcellati C. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005; 46: 386–392.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338: b1665.
    OpenUrl
  8. ↵
    Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens. 2009; 27: 923–934.
    OpenUrlCrossRefPubMed
  9. ↵
    JATOS Study Group. Principal results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS). Hypertens Res. 2008; 31: 2115–2127.
    OpenUrlCrossRefPubMed
  10. ↵
    Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009; 374: 525–533.
    OpenUrlCrossRefPubMed
  11. ↵
    Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, Imai Y, Kikuchi K, Ito S, Eto T, Kimura G, Imaizumi T, Takishita S, Ueshima H, for the Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in Elderly Isolated Systolic Hypertension study. Hypertension. 2010; 56: 196–202.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst. 2006; 7: 61–63.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363: 2022–2031.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
August 2010, Volume 56, Issue 2
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Treating Hypertension in Elderly
    • Does Evidence Support an Aggressive Systolic BP Target in the Elderly?
    • What to Conclude, Then?
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    “The Lower the BP the Better” Paradigm in the Elderly
    Fabio Angeli, Gianpaolo Reboldi and Paolo Verdecchia
    Hypertension. 2010;56:182-184, originally published June 7, 2010
    https://doi.org/10.1161/HYPERTENSIONAHA.110.150763

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    “The Lower the BP the Better” Paradigm in the Elderly
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    “The Lower the BP the Better” Paradigm in the Elderly
    Fabio Angeli, Gianpaolo Reboldi and Paolo Verdecchia
    Hypertension. 2010;56:182-184, originally published June 7, 2010
    https://doi.org/10.1161/HYPERTENSIONAHA.110.150763
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Basic, Translational, and Clinical Research
    • Clinical Studies
  • Epidemiology, Lifestyle, and Prevention
    • Epidemiology
  • Cardiology
    • Etiology
      • Epidemiology
      • Hypertension
        • Clinical Studies

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured